Yumanity Therapeutics, Inc. was awarded a $500,000 research grant from The Michael J. Fox Foundation for Parkinson's Research to further investigate preclinical efficacy and biomarker development for YTX-7739, which is in clinical development for the treatment of Parkinson's disease. YTX-7739 is Yumanity Therapeutics' proprietary lead small-molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase. Yumanity recently announced top-line results from its successful Phase 1b clinical trial for YTX-7739 in patients with Parkinson's disease and is expecting to start its randomized Phase 2 clinical trial in 2022.